Document resource
We read with great interest the SIMBA trial, a triple-blind, randomised, placebo-controlled superiority study of simvastatin versus placebo for prevention of recurrent acute pancreatitis (RAP) and acute-on-chronic inflammatory flares of chronic pancreatitis (CP).1 In the intention-to-treat analysis, recurrence occurred in 46.2% assigned to simvastatin vs 44.4% assigned to placebo (OR 1.07, 95% CI 0.43 to 2.66; p=0.88), with no difference in time to recurrence. New-onset diabetes occurred in four participants receiving simvastatin, raising safety questions. The investigators concluded that simvastatin did not reduce recurrent episodes or CP flares; importantly, the trial was terminated early after slow recruitment, and interim conditional power was very low, making statistical significance unlikely even with planned enrolment.